Digital Intervention to Optimize LDL-C and Lipid Management in Patients at High and Very High Cardiovascular Risk: The Findings of the REMEXDIS Study in Real-World Clinical Practice

Inadequate management of low-density lipoprotein cholesterol (LDL-C) in patients at high and very high cardiovascular risk remains a major clinical challenge due to poor adherence, therapeutic inertia, and limited follow-up. Digital tools may improve adherence, prompt treatment intensification, and increase attainment of lipid targets. We evaluated the REMEXDIS mobile app in a prospective, comparative, multicenter, real-world, quasi-experimental study with 12 months’ follow-up among adults at high or very high cardiovascular risk treated at Mexican Social Security Institute facilities. Materials and methods: Participants voluntarily downloaded the app, which provided reminders, personalized feedback, and physician alerts when LDL-C exceeded targets. Longitudinal changes among app users were assessed over 12 months, and 12-month LDL-C outcomes were additionally compared between app users and a contemporaneous non-app comparison group using multivariable adjusted analyses. Results: Median age was 64 years and 54.3% were female. Among 14,497 app users with paired baseline and 12-month data, median LDL-C decreased from 60 to 48 mg/dL, while LDL-C target attainment increased from 55.4% to 77.5%. In the high-risk subgroup, target attainment increased from 61.3% to 85.8%, and in the very-high-risk subgroup from 48.9% to 68.4%. Monotherapy decreased from 84.2% to 54.0%, whereas dual therapy increased from 13.4% to 43.8%. In adjusted analyses, app use was associated with an 11.53 mg/dL lower LDL-C level at 12 months compared with non-app use (95% CI, 10.08–12.98; p < 0.01) and with higher odds of achieving the LDL-C target at 12 months (adjusted OR 2.89, 95% CI, 2.54–3.28; p < 0.01). Conclusions: In this large real-world cohort, REMEXDIS app use was associated with more favorable 12-month LDL-C levels and target attainment after multivariable adjustment. However, because app use was not randomized, these findings should be interpreted as associations rather than causal effects. Further studies are needed to evaluate long-term clinical outcomes, cost-effectiveness, and the contribution of specific components of the digital intervention.

Authors

Institutions

Publication Details

Journal
Data
Published
2026-09-24
DOI
https://doi.org/10.3390/data11100250
Primary Topic
Medication Adherence and Compliance
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
article

Digital Intervention to Optimize LDL-C and Lipid Management in Patients at High and Very High Cardiovascular Risk: The Findings of the REMEXDIS Study in Real-World Clinical Practice

Ivan Cruz‐Aceves, Juan Pablo Fernández-Hernández, Sergio Solorio, Dra. Gabriela Borrayo Sánchez et al.
Data
Medication Adherence and Compliance
article

Digital Intervention to Optimize LDL-C and Lipid Management in Patients at High and Very High Cardiovascular Risk: The Findings of the REMEXDIS Study in Real-World Clinical Practice

Ivan Cruz‐Aceves, Juan Pablo Fernández-Hernández, Sergio Solorio, Dra. Gabriela Borrayo Sánchez, Martha Alicia Hernández-Gonzalez, Miguel-Angel Gil-Rios, Laura Cecilia Bonifaz Alfonzo
article en

Abstract

Inadequate management of low-density lipoprotein cholesterol (LDL-C) in patients at high and very high cardiovascular risk remains a major clinical challenge due to poor adherence, therapeutic inertia, and limited follow-up. Digital tools may improve adherence, prompt treatment intensification, and increase attainment of lipid targets. We evaluated the REMEXDIS mobile app in a prospective, comparative, multicenter, real-world, quasi-experimental study with 12 months’ follow-up among adults at high or very high cardiovascular risk treated at Mexican Social Security Institute facilities. Materials and methods: Participants voluntarily downloaded the app, which provided reminders, personalized feedback, and physician alerts when LDL-C exceeded targets. Longitudinal changes among app users were assessed over 12 months, and 12-month LDL-C outcomes were additionally compared between app users and a contemporaneous non-app comparison group using multivariable adjusted analyses. Results: Median age was 64 years and 54.3% were female. Among 14,497 app users with paired baseline and 12-month data, median LDL-C decreased from 60 to 48 mg/dL, while LDL-C target attainment increased from 55.4% to 77.5%. In the high-risk subgroup, target attainment increased from 61.3% to 85.8%, and in the very-high-risk subgroup from 48.9% to 68.4%. Monotherapy decreased from 84.2% to 54.0%, whereas dual therapy increased from 13.4% to 43.8%. In adjusted analyses, app use was associated with an 11.53 mg/dL lower LDL-C level at 12 months compared with non-app use (95% CI, 10.08–12.98; p < 0.01) and with higher odds of achieving the LDL-C target at 12 months (adjusted OR 2.89, 95% CI, 2.54–3.28; p < 0.01). Conclusions: In this large real-world cohort, REMEXDIS app use was associated with more favorable 12-month LDL-C levels and target attainment after multivariable adjustment. However, because app use was not randomized, these findings should be interpreted as associations rather than causal effects. Further studies are needed to evaluate long-term clinical outcomes, cost-effectiveness, and the contribution of specific components of the digital intervention.

DataVol. 11(10)
Universidad de Guanajuato (MX), Mexican Social Security Institute (MX), Universidad Autónoma de la Ciudad de México (MX), Mathematics Research Center (MX), Hospital General De Zona (MX), Instituto Tecnológico de León (MX), Hospital de Especialidades (MX), Universidad Nacional Autónoma de México (MX)
No poverty
Openalex Percentile: Top 8%
Medication Adherence and Compliance
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.